You are here

Retinoids as Novel Treatment of Ischemic Stroke

Award Information
Agency: Department of Health and Human Services
Branch: National Institutes of Health
Contract: 1R41NS053041-01A1
Agency Tracking Number: NS053041
Amount: $130,453.00
Phase: Phase I
Program: SBIR
Solicitation Topic Code: N/A
Solicitation Number: PHS2006-2
Solicitation Year: 2006
Award Year: 2006
Award Start Date (Proposal Award Date): N/A
Award End Date (Contract End Date): N/A
Small Business Information
ACRYMED, INC. 9560 SW Nimbus Ave.
Beaverton, OR 97008
United States
HUBZone Owned: Unavailable
Woman Owned: No
Socially and Economically Disadvantaged: No
Principal Investigator
 (503) 494-4979
Business Contact
Phone: (503) 624-9830
Research Institution

DESCRIPTION (provided by applicant): Stroke is the third leading cause of death in the U.S. and a major source of disability. Ischemic stroke, the most common type, is associated with a dramatic increase in calcium influx in brain tissue, an increased production in reactive oxygen species (ROS), cell death and inflammation. Studies by the PI have shown that retinoids block neuronal voltage-gated calcium channels. Studies by others suggest that retinoids reduce tissue levels of reactive oxygen species and prevents cellular apoptosis, increase tissue plasminogen activator, favorably modify the balance of pro-inflammatory and inflammatory cytokines and attenuate inflammation in vivo. Together, the data suggest that retinoids might be neuroprotective and potentially useful in the treatment of ischemic stroke. Our goal is to demonstrate that retinoids have neuroprotective activity in vivo. Specifically, we propose to demonstrate that treatment with retinoids: 1) attenuates post-stroke motor deficits using a mouse model of permanent focal cerebral ischemia (middle cerebral artery occlusion), 2) reduces cerebral infarct size, and 3) reduces the expression of the biochemical markers of apoptosis, ROS production and inflammation in the ischemic brain. The project will provide a rationale for the development of retinoid-based formulations to treat ischemic stroke and for the screening of retinoid libraries in search of more potent compounds.

* Information listed above is at the time of submission. *

US Flag An Official Website of the United States Government